Updates are available Correction dated 2025-08-27

Article History

Accepted: 4 May 2025

First Online: 30 June 2025

Change Date: 27 August 2025

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s11523-025-01171-3

Declarations

:

: Open Access funding enabled and organized by Projekt DEAL. This research received no specific funding, and no funding was provided for publication of this article.

: KD has received honoraria from AstraZeneca and support for travel, accommodation, and expenses from Servier, GSK, Bristol Myers Squibb, and AstraZeneca. MK has received speaker honoraria and travel support from Recordati, Eisai, and Lilly. DZ has received travel support from AstraZeneca, Amgen, and BMS and honoraria from AstraZeneca. LW has received honoraria from Roche and Servier and support for travel from Amgen and Merck. SB has received honoraria for scientific presentations from Celgene, Servier, and MSD; fees for consultancy or advisory roles from Celgene, Servier, Incyte, Janssen-Cilag, AstraZeneca, MSD, and Bristol Myers Squibb; and support for travel, accommodation, and expenses from Lilly. MvB has received research support from and serves on the speakers’ bureau for Gilead, Miltenyi Biotec, Merck Sharp & Dohme, Roche, Mologen, Novartis, Astellas, and Bristol Myers Squibb. VH has received research funding paid to his institution from Merck, Amgen, and Roche; fees for consultancy and advisory roles from Merck, Amgen, Roche, MSD, Bristol Myers Squibb, MSD Oncology, Novartis, Pierre Fabre, TERUMO, GSK, Servier/Pfizer, AstraZeneca, Oncosil, and Nordic Bioscience; honoraria from Roche, Amgen, Sanofi, Merck, Servier, Pfizer, Pierre Fabre, AstraZeneca, MSD, and Seagen; and support for travel, accommodation, and expenses from Merck. CBW has received honoraria from Amgen, Bayer, BMS, Chugai, Celgene, Falk, GSK, MSD, Merck, Janssen, Ipsen, Roche, Servier, SIRTeX, and Taiho; has served on advisory boards for Bayer, BMS, Celgene, Janssen, MSD, Servier, Shire/Baxalta, Rafael Pharmaceuticals, RedHill, and Roche; has received travel support from Bayer, Celgene, Janssen, RedHill, Roche, Servier, and Taiho; and has received research grants (institutional) from Roche. CBW serves as an officer for ESMO, Deutsche Krebshilfe, and Arbeitsgemeinschaft internistische Onkologie and is a member of the EU Commission expert group: Mission Board for cancer. KH has received Honoraria from Amgen, BMS, Lilly, Merck, Roche, Taiho, Servier and streamedup!, fees for consulting or advisory role from Amgen, Servier, MSD (Institutional), Merck and Janssen; has received travel support from Amgen, Merck and Servier. CJA, CSp, RS, SN, MR, CSc, MA, JW, CS-T, JR, MZ, TK, JK, AJ, FK and AT, have no conflicts of interest that might be relevant to the contents of this manuscript.

: This retrospective chart review study involving human participants was undertaken in accordance with the principles of the Declaration of Helsinki and its later amendments. The study was approved by the local ethics committee of the Ludwig-Maximilians-University Munich (project number 21-0869).

: Not applicable.

: Not applicable.

: The datasets generated and analyzed during the current study are available from the corresponding author upon reasonable request.

: Not applicable.

: All authors contributed to the study conception and design. Klara Dorman and Kathrin Heinrich prepared the material collected and analyzed the data. Klara Dorman wrote the first draft of the manuscript, and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.